Impact of Aerobic Training and Combined in Inflammatory Markers in Patients With Adolescent Idiopathic Scoliosis

September 5, 2023 updated by: Profa. Dra. Vera Lúcia dos Santos Alves, Faculdade de Ciências Médicas da Santa Casa de São Paulo

Inflammatory markers have been analyzed in several diseases of unknown etiology, in the expectation of increasing therapeutic perspectives. This possibility arises from the different levels of tissue injury with low-grade chronic inflammation that have been observed in studies in which the markers were not evaluated traditionally, and today have influenced clinical management.

The investigators aimed, therefore, to evaluate the inflammatory markers in patients with AIS before and after aerobic and combined exercise training.

Study Overview

Detailed Description

Inflammatory markers have not been evaluated in adolescent idiopathic scoliosis (AIS), but this deformity potentially involves various musculoskeletal structures permanently, which justifies the analysis. A low-grade chronic inflammation may be related to the lower capacity in exercise performance observed in this population, which must be stimulated to perform standardized physical activity.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sao Paulo, Brazil, 01221-020
        • Santa Casa of Sao Paulo Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • thoracic curvature ≥ 45 degrees
  • indication for surgical treatment of spinal deformity
  • absence of pulmonary, cardiac, articular or neurological disorder, atopic dermatitis and previous or current allergy
  • agree part in the research with a assent statement and the person responsible with the consent form and informed

Exclusion Criteria:

  • acknowledged chronic liver or kidney inflammatory disease
  • use of corticosteroids, acetylsalicylic acid or other nonhormonal anti-inflammatory clinical or laboratorial evidence of infection
  • severe obesity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: combined group (treadmill and resisted)
- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
Active Comparator: aerobic group (treadmill)
10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
interleukin 1
Time Frame: change from baseline in interleukin 1 at 3 months
Inflammatory Markers
change from baseline in interleukin 1 at 3 months
interleukin 6
Time Frame: change from baseline in interleukin 6 at 3 months
Inflammatory Markers
change from baseline in interleukin 6 at 3 months
interleukin 8
Time Frame: change from baseline in interleukin 8 at 3 months
Inflammatory Markers
change from baseline in interleukin 8 at 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
distance in six-minute walk test
Time Frame: change from baseline in distance at 3 months
analysis of distance
change from baseline in distance at 3 months
oxygen saturation in six-minute walk test
Time Frame: change from baseline in oxygen saturation at 3 months
analysis of oxygen saturation at end of test
change from baseline in oxygen saturation at 3 months
systolic blood pressure in six-minute walk test
Time Frame: change from baseline in systolic blood pressure at 3 months
analysis of systolic blood pressure at end of test
change from baseline in systolic blood pressure at 3 months
diastolic blood pressure in six-minute walk test
Time Frame: change from baseline in diastolic blood pressure at 3 months
analysis of diastolic blood pressure at end of test
change from baseline in diastolic blood pressure at 3 months
heart rate in six-minute walk test
Time Frame: change from baseline in heart rate at 3 months
analysis of heart rate at end of test
change from baseline in heart rate at 3 months
respiratory frequency in six-minute walk test
Time Frame: change from baseline in respiratory frequency at 3 months
analysis of respiratory frequency at end of test
change from baseline in respiratory frequency at 3 months
Borg scale in six-minute walk test
Time Frame: change from baseline in Borg scale at 3 months
analysis of Borg scale at end of test
change from baseline in Borg scale at 3 months
forced vital capacity (FVC)
Time Frame: change from baseline at 3 months
analyzed in liters or % of predicted of lung capacity variation from baseline at 3 months
change from baseline at 3 months
maximal inspiratory pressure (MIP)
Time Frame: change from baseline at 3 months
analysis of maximal inspiratory pressure variation (cmH2O)
change from baseline at 3 months
maximal expiratory pressure (MEP)
Time Frame: change from baseline at 3 months
analysis of maximal expiratory pressure variation (cmH2O)
change from baseline at 3 months
peak expiratory flow
Time Frame: change from baseline at 3 months
peak expiratory flow variation analysis in liters / minute (l/min)
change from baseline at 3 months
forced expiratory volume in the first second (FEV1)
Time Frame: change from baseline at 3 months
analyzed in liters or % of predicted of lung volume variation from baseline at 3 months
change from baseline at 3 months
forced expiratory volume in the first second (FEV1) / forced vital capacity (FVC)
Time Frame: change from baseline at 3 months
Analysis (%) of the relationship between FEV1 and FVC with variation from baseline at 3 months
change from baseline at 3 months
FORCED EXPIRATORY FRACTION (FEF25-75%)
Time Frame: change from baseline at 3 months
analyzed in milliliters (ml) of lung volume variation from baseline at 3 months
change from baseline at 3 months
FORCED EXPIRATORY FRACTION (FEF25-75%) / forced vital capacity (FVC)
Time Frame: change from baseline at 3 months
Analysis (%) of the relationship between FEV1 and FVC with variation from baseline at 3 months
change from baseline at 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

March 31, 2015

First Submitted That Met QC Criteria

April 9, 2015

First Posted (Estimated)

April 10, 2015

Study Record Updates

Last Update Posted (Actual)

September 6, 2023

Last Update Submitted That Met QC Criteria

September 5, 2023

Last Verified

November 1, 2019

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Scoliosis

Clinical Trials on combined exercise

Subscribe